{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-057139","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.494888+00:00","generated_at":"2026-05-18T22:46:25.355992+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"InMed's INM-901 reduces neuroinflammation markers in Alzheimer's ex vivo study","bullets":["INM-901 statistically significantly reduced pro-inflammatory cytokines IL-6, IL-1β, IL-2, and KC/Gro in LPS-induced ex vivo model.","INM-901 significantly reduced inflammasome marker NLRP3, a key contributor to neurodegeneration.","Reduction of pro-inflammatory markers independent of amyloid beta or tau pathology.","Company plans to advance INM-901 through additional preclinical studies with IND-enabling studies to follow."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-057139","json":"https://secwatch.observer/filing/0001213900-25-057139.json","markdown":"https://secwatch.observer/filing/0001213900-25-057139.md","text":"https://secwatch.observer/filing/0001213900-25-057139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025057139/0001213900-25-057139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025057139/ea0246768-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T22:46:25.355992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}